Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter  T. Blanchon  Clinical Microbiology and Infection  Volume 19, Issue 2, Pages 196-203 (February 2013) DOI: 10.1111/j.1469-0691.2011.03751.x Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1. Proportion of the 141 influenza A-infected patients with alleviation of symptoms when treated with oseltamivir plus placebo according to sex (female dark lines, male grey lines) and days 0–2 compliance (full compliance continuous lines, incomplete compliance dotted lines). Alleviation of symptoms defined by the presence of no symptoms of nasal stuffiness, sore throat, cough, muscle aches, tiredness-fatigue, feverishness, and headache or only mild ones, for at least 24 h. Clinical Microbiology and Infection 2013 19, 196-203DOI: (10.1111/j.1469-0691.2011.03751.x) Copyright © 2013 European Society of Clinical Infectious Diseases Terms and Conditions